Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

CONCLUSION: This triple combining in situ vaccine induced intensive antitumor responses, mediated effective systemic tumor control and survival benefit, and displayed impressive synergistic antitumor effect with checkpoint blockade therapy. These data preliminary confirmed the efficacy, feasibility and safety of the triple combining in situ vaccine, suggesting its great application potential as both monotherapy and a part of combined immunotherapeutic regimens in clinical scenario.PMID:37700338 | DOI:10.1186/s12967-023-04504-w

Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Zhichen Sun Yanhong Chu Jie Xiao Yueling Yang Fanyan Meng Xinyue Wang Yanbing Dong Junmeng Zhu Yirong Wu Lanqun Qin Yaohua Ke Baorui Liu Qin Liu Source Type: research